CDK9 and diffuse large B-cell lymphoma: PRT2527: PRT2527 is a selective and potent cyclin-dependent kinase 9 inhibitor that exhibits antiproliferative and proapoptotic activity in DLBCL, CLL, and mantle cell lymphoma (MCL) cell lines [82].